Ipca Laboratories Limited Q1, Q2, Q3, Q4, FY 2017-18, FY 2016-17 Standalone / Consolidated Results, Revenues, Net Profit, Tax, EPS, Live Chart …
Ipca Laboratories Limited Company Profile :
Ipca Laboratories Limited is an Indian company engaged in pharmaceuticals business. The Company is a manufacturer and supplier of over 10 active pharmaceutical ingredients (APIs).
It offers APIs, such as atenolol, hydroxychloroquine sulfate, morantel citrate, pyrantel pamoate and zaltoprofen. It offers brands, such as Zerodol, Lariago, HCQS Perinorm, Rapither, Tenoric, Lumerax, Etova, Malirid and Folitrax.
BSE Code : 524494
NSE Symbol : IPCALAB
ISIN No. : INE571A01020
Industry : Pharmaceuticals
Face Value : Rs. 2.00
If you are an investor who has shares of Ipca Laboratories or you are an stock market analyst then i am sure you might for Quarterly Results of Ipca Laboratories.
In this article you will find Q1, Q2, Q3, Q4 and FY 2016-17 Results of Ipca Laboratories. That’s not all, you can compare those results with previous year i.e., FY 2015-16 Results of Ipca Laboratories.
Ipca Laboratories Q1 Results 2016-17 :
Ipca Laboratories will announce its Q1 FY 2016-17 Results in the month of July 2016. We will update the table below once the results are announced.
|(Values in Cr.)||Q1 Standalone||Q1 Consolidated|
Ipca Laboratories will announce its Q2 FY 2016-17 Results in the month of October 2016.
Ipca Laboratories will announce its Q3 FY 2016-17 Results in the month of January 2017.
Ipca Laboratories will announce its Q4 FY 2016-17 Results in the month of April 2017.
Ipca Laboratories will announce its FY 2016-17 Results in the month of April 2017.
Note : We will update the results table above as and when results are announced. Visit again.
Ipca Laboratories Previous Year’s Results (FY 2015-16) :
|(Values in Cr.)||Standalone||Consolidated|
Note : If you like this information about Ipca Laboratories Quarterly Results, then please share it with all your friends, relatives and other investors on Facebook, Twitter, WhatsApp, Email, etc.